Collapse all
The framework reveals a high-value clinical decision support tool that shifts oncology from reactive imaging to proactive molecular monitoring. While the value proposition is strong for high-end cancer centers, the model is heavily dependent on the high-frequency sampling infrastructure of partners like Roche and Mayo Clinic.
4 Diagnostic Labs (e.g., Roche) Provides the high-sensitivity NGS and liquid biopsy assays required to generate the raw VAF and bTMB data. Academic Medical Centers Institutions like MSKCC and Mayo Clinic provide the clinical validation environment and patient cohorts for NSCLC. Regulatory Bodies (FDA/EMA) Essential for certifying the software as a Class II/III medical device for clinical decision support. Cloud Infrastructure Providers Secure, HIPAA-compliant computing environments to process longitudinal genomic data streams. 4 VAF Trend Analysis Developing algorithms to distinguish clinically significant VAF increases from biological noise or assay variance. Resistance Marker Mapping Maintaining a curated database of actionable resistance mutations (e.g., MET, BRAF) to trigger clinician alerts. Clinical Workflow Integration Designing the UI/UX to fit into the oncologist's existing review cycle without adding excessive administrative burden. Validation Studies Conducting retrospective and prospective trials to correlate molecular progression with radiographic relapse. 4 Proprietary Analysis Algorithms The software logic that converts raw sequencing data into a longitudinal risk trajectory. Genomic Data Sets Access to longitudinal ctDNA data from NSCLC patients to refine predictive thresholds. Bioinformatics Talent Specialists capable of handling ultra-deep sequencing data and clonal evolution modeling. Clinical Partnerships Established relationships with oncology departments for real-world evidence gathering. 4 Lead-Time Advantage Detects drug resistance via VAF increases before tumors become visible on CT or PET scans. Precision Therapy Switching Identifies specific actionable mutations, allowing oncologists to switch to the correct second-line therapy immediately. Non-Invasive Monitoring Replaces the need for repeated invasive tissue biopsies to track clonal evolution. Reduced Treatment Futility Prevents patients from remaining on ineffective therapies by signaling molecular progression early. 3 Clinical Co-Development Working closely with lead oncologists at Mayo Clinic to refine the 'trigger' thresholds for therapy changes. B2B Enterprise Support Providing dedicated technical integration and training for hospital IT and pathology departments. Evidence-Based Trust Publishing peer-reviewed data on the tool's positive predictive value compared to imaging. 3 Direct B2B Sales Selling licenses directly to large oncology networks and comprehensive cancer centers. Diagnostic Partnerships Bundling the analysis software with liquid biopsy kits provided by companies like Roche. Medical Conferences Presenting results at ASCO or ESMO to drive adoption among key opinion leaders (KOLs). 3 Tertiary Cancer Centers High-volume institutions like MSKCC treating advanced NSCLC with targeted therapies. Precision Medicine Labs Commercial labs that perform NGS and want to offer a value-added longitudinal monitoring service. Pharmaceutical Companies Companies running clinical trials for second-line therapies who need precise markers of progression. 3 R&D and Bioinformatics High costs associated with developing and validating the VAF tracking algorithms. Regulatory Compliance Significant expenditure for FDA/EMA clearance and maintaining medical device quality standards. Cloud Computing Costs Costs for processing and storing large-scale genomic data files (BAM/VCF) over time. 3 Per-Patient Subscription A recurring fee for monitoring a patient over a specific treatment cycle (e.g., 6 months). Enterprise Licensing Annual site licenses for large hospital systems to integrate the tool into their EHR. Pharma Partnership Fees Fees for providing the tool as a companion diagnostic in clinical trials for new oncology drugs. The idea identifies specific high-value beneficiaries like Mayo Clinic and Roche, making it appropriate to map out the value proposition and revenue streams. · Generated 2026-09-24 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated